Journal article · 2022 · Open access

The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner

Janet K. Peper-Gabriel, Marina Pavlidou, Lucia Pattarini, Aizea Morales‐Kastresana, Thomas J. Jaquin, Catherine Gallou, Eva-Maria Hansbauer, Marleen Richter, Hélène Lelièvre, Alix Scholer-Dahirel, Birgit Bossenmaier, Celine Sancerne and 7 more

Clinical Cancer Research, 28(15), 3387–3399 · Published 4 February 2022 · DOI 10.1158/1078-0432.ccr-21-2762

Open PDFView at the publisherCite this paper

In brief

“The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner” is a 2022 journal article by Janet K. Peper-Gabriel and 18 co-authors, published in Clinical Cancer Research. OpenAlex counts 57 citations as of 18 November 2026, which puts it in the top 1% of works published in 2022 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Clinical Cancer Research.

Citations
57
Most cited in
2024 (17)
Field-weighted impact
4.93
References
71
Authors
19

Abstract

PURPOSE: While patients responding to checkpoint blockade often achieve remarkable clinical responses, there is still significant unmet need due to resistant or refractory tumors. A combination of checkpoint blockade with further T-cell stimulation mediated by 4-1BB agonism may increase response rates and durability of response. A bispecific molecule that blocks the programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis and localizes 4-1BB costimulation to a PD-L1-positive (PD-L1+) tumor microenvironment (TME) or tumor draining lymph nodes could maximize antitumor immunity and increase the therapeutic window beyond what has been reported for anti-4-1BB mAbs. EXPERIMENTAL DESIGN: We generated and characterized the PD-L1/4-1BB bispecific molecule PRS-344/S095012 for target binding and functional activity in multiple relevant in vitro assays. Transgenic mice expressing human 4-1BB were transplanted with human PD-L1-expressing murine MC38 cells to assess in vivo antitumoral activity. RESULTS: PRS-344/S095012 bound to its targets with high affinity and efficiently blocked the PD-1/PD-L1 pathway, and PRS-344/S095012-mediated 4-1BB costimulation was strictly PD-L1 dependent. We demonstrated a synergistic effect of both pathways on T-cell stimulation with the bispecific PRS-344/S095012 being more potent than the combination of mAbs. PRS-344/S095012 augmented CD4-positive (CD4+) and CD8-positive (CD8+) T-cell effector functions and enhanced antigen-specific T-cell stimulation. Finally, PRS-344/S095012 demonstrated strong antitumoral efficacy in an anti-PD-L1-resistant mouse model in which soluble 4-1BB was detected as an early marker for 4-1BB agonist activity. CONCLUSIONS: The PD-L1/4-1BB bispecific PRS-344/S095012 efficiently combines checkpoint blockade with a tumor-localized 4-1BB-mediated stimulation burst to antigen-specific T cells, more potent than the combination of mAbs, supporting the advancement of PRS-344/S095012 toward clinical development. See related commentary by Shu et al., p. 3182.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Peper-Gabriel, J. K., Pavlidou, M., Pattarini, L., Morales‐Kastresana, A., Jaquin, T. J., Gallou, C., Hansbauer, E.-M., Richter, M., Lelièvre, H., Scholer-Dahirel, A., Bossenmaier, B., Sancerne, C., Riviere, M., Grandclaudon, M., Zettl, M., Aiba, R. S. B., Rothe, C., Blanc, V., & Olwill, S. A. (2022). The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner. Clinical Cancer Research, 28(15), 3387–3399. https://doi.org/10.1158/1078-0432.ccr-21-2762

MLA 9

Peper-Gabriel, Janet K., et al. “The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.” Clinical Cancer Research, vol. 28, no. 15, 2022, pp. 3387–3399. https://doi.org/10.1158/1078-0432.ccr-21-2762.

Chicago

Peper-Gabriel, Janet K., Marina Pavlidou, Lucia Pattarini, Aizea Morales‐Kastresana, Thomas J. Jaquin, Catherine Gallou, Eva-Maria Hansbauer, et al. 2022. “The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.” Clinical Cancer Research 28 (15): 3387–3399. https://doi.org/10.1158/1078-0432.ccr-21-2762.

Harvard

Peper-Gabriel, J. K. et al. (2022) ‘The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner’, Clinical Cancer Research, 28(15), pp. 3387–3399. doi:10.1158/1078-0432.ccr-21-2762.

IEEE

J. K. Peper-Gabriel et al., “The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner,” Clinical Cancer Research, vol. 28, no. 15, pp. 3387–3399, 2022, doi: 10.1158/1078-0432.ccr-21-2762.

BibTeX

@article{pepergabriel2022bispecific,
  title     = {{The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner}},
  author    = {Peper-Gabriel, Janet K. and Pavlidou, Marina and Pattarini, Lucia and Morales‐Kastresana, Aizea and Jaquin, Thomas J. and Gallou, Catherine and Hansbauer, Eva-Maria and Richter, Marleen and Lelièvre, Hélène and Scholer-Dahirel, Alix and Bossenmaier, Birgit and Sancerne, Celine and Riviere, Matthieu and Grandclaudon, Maximilien and Zettl, Markus and Aiba, Rachida S. Bel and Rothe, Christine and Blanc, Veronique and Olwill, Shane Anthony},
  journal   = {Clinical Cancer Research},
  year      = {2022},
  volume    = {28},
  number    = {15},
  pages     = {3387--3399},
  doi       = {10.1158/1078-0432.ccr-21-2762},
  url       = {https://doi.org/10.1158/1078-0432.ccr-21-2762}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202299
20231010
20241717
20251010
20261111

Its field-weighted citation impact is 4.93: it has been cited 4.93 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers

  • PD-1/PD-L1 blockade
  • T cell stimulation
  • tumor microenvironment
  • anti-PD-L1 resistance
  • CD4 and CD8 T cells
  • antigen-specific T cell responses

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Peper-Gabriel, J. K., Pavlidou, M., Pattarini, L., Morales‐Kastresana, A., Jaquin, T. J., Gallou, C., Hansbauer, E.-M., Richter, M., Lelièvre, H., Scholer-Dahirel, A., Bossenmaier, B., Sancerne, C., Riviere, M., Grandclaudon, M., Zettl, M., Aiba, R. S. B., Rothe, C., Blanc, V., & Olwill, S. A. (2022). The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner. Clinical Cancer Research, 28(15), 3387–3399. https://doi.org/10.1158/1078-0432.ccr-21-2762

How many times has this paper been cited?

57 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Clinical Cancer Research: sign in and open the PDF from this page.

Who wrote this paper?

Janet K. Peper-Gabriel, Marina Pavlidou, Lucia Pattarini, Aizea Morales‐Kastresana, Thomas J. Jaquin, Catherine Gallou, Eva-Maria Hansbauer, Marleen Richter, Hélène Lelièvre, Alix Scholer-Dahirel, Birgit Bossenmaier, Celine Sancerne and 7 more.

What is the DOI of this paper?

10.1158/1078-0432.ccr-21-2762, permanently at https://doi.org/10.1158/1078-0432.ccr-21-2762. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.